Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 11:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 67 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Nephrotic Syndrome Clear all
Recruiting Not applicable Interventional

NEPTUNE Match Study

NCT04571658
View directory record Official record
Conditions
Nephrotic Syndrome in Children, Focal Segmental Glomerulosclerosis, Minimal Change Disease, Minimal Change Nephrotic Syndrome, Membranous Nephropathy, FSGS, MCD, MCD - Minimal Change Disease, Alport Syndrome
Interventions
Communication
Other
Lead sponsor
University of Michigan
Other
Eligibility
1 Year to 80 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
16
States / cities
Atlanta, Georgia • Chicago, Illinois • Kansas City, Kansas + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jul 22, 2026, 11:00 AM EDT
Terminated Phase 2 Interventional

An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases

NCT04950114
View directory record Official record
Conditions
Kidney Diseases, Glomerulosclerosis, Focal Segmental Nephrosis, Lipoid Urologic Disease, Glomerulonephritis, Nephritis, Nephrosis
Interventions
GFB-887
Drug
Lead sponsor
Goldfinch Bio, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
17
States / cities
Los Angeles, California • Northridge, California • Victorville, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Jul 22, 2026, 11:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Prospective Multi-dose Study of Apixaban in Subjects With Nephrotic Syndrome

NCT04278729
View directory record Official record
Conditions
Nephrotic Syndrome, Membranous Nephropathy
Interventions
Apixaban 5 MG
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 79 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 25, 2023 · Synced Jul 22, 2026, 11:00 AM EDT
Recruiting Not applicable Interventional

taVNS for FRNS in Children

NCT05588063
View directory record Official record
Conditions
Nephrotic Syndrome in Children, Minimal Change Disease, Focal Segmental Glomerulosclerosis
Interventions
Transcutaneous auricular vagus nerve stimulation, Sham device
Device
Lead sponsor
Northwell Health
Other
Eligibility
3 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
New Hyde Park, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 22, 2026, 11:00 AM EDT
Completed Phase 3 Interventional Results available

Adrenocorticotropic Hormone (ACTH) for Frequently Relapsing and Steroid Dependent Nephrotic Syndrome

NCT02132195
View directory record Official record
Conditions
Nephrotic Syndrome
Interventions
ACTH
Drug
Lead sponsor
Emory University
Other
Eligibility
2 Years to 20 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • Wilmington, Delaware + 13 more
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Jul 22, 2026, 11:00 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Glucocorticoid-induced Osteopenia in Children

NCT00289328
View directory record Official record
Conditions
Crohn's Disease, Nephrotic Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
5 Years to 21 Years
Enrollment
550 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 1, 2010 · Synced Jul 22, 2026, 11:00 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

NCT06500702
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
Interventions
frexalimab, brivekimig, rilzabrutinib, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
16 Years to 75 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
16
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 22, 2026, 11:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

FIH Ph 1 Study of TRPC5 Channel Inhibitor GFB-887 in Healthy Subjects

NCT03970122
View directory record Official record
Conditions
Healthy Volunteers
Interventions
GFB-887, Placebo
Drug
Lead sponsor
Goldfinch Bio, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Jul 22, 2026, 11:00 AM EDT
Completed Phase 2 Interventional

Once-A-Month Steroid Treatment for Patients With Focal Segmental Glomerulosclerosis

NCT00004990
View directory record Official record
Conditions
Glomerulonephritis, Nephrotic Syndrome
Interventions
Dexamethasone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 11:00 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Inflammatory and Immune Profiling of Kidney Tissue Obtained From Patients With Newly Diagnosed Kidney Disease

NCT01156428
View directory record Official record
Conditions
Proteinuria, Kidney Injury, Chronic Kidney Disease
Interventions
Not listed
Lead sponsor
The Rogosin Institute
Other
Eligibility
18 Years to 90 Years
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 14, 2024 · Synced Jul 22, 2026, 11:00 AM EDT
Recruiting No phase listed Observational

Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.

NCT05505500
View directory record Official record
Conditions
Fluid Overload, Glomerulosclerosis, Focal Segmental, Edema, Membranous Nephropathy, Minimal Change Disease, Minimal Change Nephrotic Syndrome, IgM Nephropathy, Nephrotic Syndrome, Glomerular Disease, Nephrotic Syndrome, Minimal Change, Nephrotic Syndrome in Children, Nephrotic Syndrome With Edema (Diagnosis), FSGS
Interventions
Interview
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
2 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Jul 22, 2026, 11:00 AM EDT
Suspended No phase listed Observational

Safety and Efficacy of Combination Acthar Gel and Tacrolimus in the Treatment of Steroid Resistant Nephrotic Syndrome

NCT03042637
View directory record Official record
Conditions
Nephrotic Syndrome
Interventions
Acthar Gel and Tacrolimus
Drug
Lead sponsor
Southeast Renal Research Institute
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Jul 22, 2026, 11:00 AM EDT
Completed Phase 4 Interventional Results available

Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients

NCT01386554
View directory record Official record
Conditions
Proteinuria, Idiopathic Membranous Nephropathy
Interventions
Repository Corticotropin Injection, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
14
States / cities
Sacramento, California • Stanford, California • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Jul 22, 2026, 11:00 AM EDT
Completed Phase 1 Interventional

Lipid Lowering Agents to Limit Lipid Oxidation and Activation of Clotting System in Nephrotic Syndrome

NCT01845428
View directory record Official record
Conditions
Nephrotic Syndrome, Hyperlipidemia
Interventions
Pravastatin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Jul 22, 2026, 11:00 AM EDT
Completed Phase 4 Interventional

Prospective Study Evaluating the Effect of Repository Corticotropin in the Treatment of Various Nephrotic Syndromes

NCT01021540
View directory record Official record
Conditions
Nephrotic Syndromes
Interventions
Repository corticotrophin
Drug
Lead sponsor
Arizona Kidney Disease and Hypertension Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 13, 2011 · Synced Jul 22, 2026, 11:00 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Genetic Causes of FSGS, Nephrotic Syndrome, or Kidney Failure

NCT02194582
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis, Nephrotic Syndrome, End Stage Renal Disease, Kidney Failure, Unexplained Proteinuria
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
Not listed
Enrollment
2,050 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2035
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Jul 22, 2026, 11:00 AM EDT
Completed Phase 2 Interventional

Drug Therapy in Lupus Nephropathy

NCT00001212
View directory record Official record
Conditions
Nephrotic Syndrome, Systemic Lupus Erythematosus
Interventions
prednisone, cyclophosphamide, cyclosporin A
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1986 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 8, 2008 · Synced Jul 22, 2026, 11:00 AM EDT
Recruiting No phase listed Observational

Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease

NCT05650619
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis, Minimal Change Disease, FSGS, MCD
Interventions
Biospecimen collection, Data collection
Other
Lead sponsor
University of Michigan
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Jul 22, 2026, 11:00 AM EDT
Terminated Phase 2 Interventional

Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)

NCT05441826
View directory record Official record
Conditions
Minimal Change Disease, Focal Segmental Glomerulosclerosis
Interventions
VB119
Drug
Lead sponsor
Tenet Medicines
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2024 · Synced Jul 22, 2026, 11:00 AM EDT
Recruiting No phase listed Observational

Nephrotic Syndrome Study Network

NCT01209000
View directory record Official record
Conditions
Minimal Change Disease (MCD), Membranous Nephropathy, Glomerulosclerosis, Focal Segmental
Interventions
Kidney Biopsy
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
Up to 80 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2030
U.S. locations
39
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jul 22, 2026, 11:00 AM EDT
Recruiting Phase 2 Interventional

Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

NCT00977977
View directory record Official record
Conditions
Nephrotic Syndrome, Proteinuria, Autoimmune Disease, Glomerular Disease, Membranous Glomerulonephritis
Interventions
Rituximab Infusion, Oral Cyclosporine
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 22, 2026, 11:00 AM EDT
Terminated No phase listed Observational

A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)

NCT04235621
View directory record Official record
Conditions
Glomerulosclerosis, Focal Segmental, Minimal Change Disease, Diabetic Nephropathies
Interventions
FSGS/TR-MCD, Diabetic Nephropathy (DN)
Other
Lead sponsor
Goldfinch Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
18
States / cities
Mesa, Arizona • Glendale, California • Victorville, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Jul 22, 2026, 11:00 AM EDT
Completed Not applicable Interventional

Effect of Daily Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) on Proteinuria in Pediatric Patients With Idiopathic Nephrotic Syndrome

NCT04169776
View directory record Official record
Conditions
Idiopathic Nephrotic Syndrome, Frequently Relapsing Nephrotic Syndrome
Interventions
Transcutaneous Auricular Vagus Nerve (taVNS) stimulation
Device
Lead sponsor
Northwell Health
Other
Eligibility
2 Years to 21 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Jul 22, 2026, 11:00 AM EDT
Terminated Phase 2 Interventional

A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease

NCT04387448
View directory record Official record
Conditions
Kidney Diseases, Diabetic Nephropathies, Glomerulosclerosis, Focal Segmental, Nephrosis, Lipoid, Urologic Diseases, Diabetes Complications, Diabetes Mellitus, Endocrine System Diseases, Glomerulonephritis, Nephritis, Nephrosis
Interventions
GFB-887, Placebo
Drug
Lead sponsor
Goldfinch Bio, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
74
States / cities
Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Jul 22, 2026, 11:00 AM EDT